|
1
|
Kelley RK, Bridgewater J, Gores GJ and Zhu
AX: Systemic therapies for intrahepatic cholangiocarcinoma. J
Hepatol. 72:353–363. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rahnemai-Azar AA, Weisbrod A, Dillhoff M,
Schmidt C and Pawlik TM: Intrahepatic cholangiocarcinoma: Molecular
markers for diagnosis and prognosis. Surg Oncol. 26:125–137. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Moris D, Palta M, Kim C, Allen PJ, Morse
MA and Lidsky ME: Advances in the treatment of intrahepatic
cholangiocarcinoma: An overview of the current and future
therapeutic landscape for clinicians. CA Cancer J Clin. 73:198–222.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Aoki S, Inoue K, Klein S, Halvorsen S,
Chen J, Matsui A, Nikmaneshi MR, Kitahara S, Hato T, Chen X, et al:
Placental growth factor promotes tumour desmoplasia and treatment
resistance in intrahepatic cholangiocarcinoma. Gut. 71:185–193.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hewitt DB, Brown ZJ and Pawlik TM:
Surgical management of intrahepatic cholangiocarcinoma. Expert Rev
Anticancer Ther. 22:27–38. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen Z, Jiang J, Fu N and Chen L:
Targetting ferroptosis for blood cell-related diseases. J Drug
Target. 30:244–258. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lei G, Zhuang L and Gan B: Targeting
ferroptosis as a vulnerability in cancer. Nat Rev Cancer.
22:381–396. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen J, Li X, Ge C, Min J and Wang F: The
multifaceted role of ferroptosis in liver disease. Cell Death
Differ. 29:467–480. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li D, Wang Y, Dong C, Chen T, Dong A, Ren
J, Li W, Shu G, Yang J, Shen W, et al: CST1 inhibits ferroptosis
and promotes gastric cancer metastasis by regulating GPX4 protein
stability via OTUB1. Oncogene. 42:83–98. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhou P, Chen X, Shi K, Qu H and Xia J: The
characteristics, tumorigenicities and therapeutics of cancer stem
cells based on circRNAs. Pathol Res Pract. 233:1538222022.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li H, Lan T, Liu H, Liu C, Dai J, Xu L,
Cai Y, Hou G, Xie K, Liao M, et al: IL-6-induced cGGNBP2 encodes a
protein to promote cell growth and metastasis in intrahepatic
cholangiocarcinoma. Hepatology. 75:1402–1419. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lu Q and Fang T: Circular RNA SMARCA5
correlates with favorable clinical tumor features and prognosis,
and increases chemotherapy sensitivity in intrahepatic
cholangiocarcinoma. J Clin Lab Anal. 34:e231382020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang X, Xing L, Yang R, Chen H, Wang M,
Jiang R, Zhang L and Chen J: The circACTN4 interacts with FUBP1 to
promote tumorigenesis and progression of breast cancer by
regulating the expression of proto-oncogene MYC. Mol Cancer.
20:912021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen Q, Wang H, Li Z, Li F, Liang L, Zou
Y, Shen H, Li J, Xia Y, Cheng Z, et al: Circular RNA ACTN4 promotes
intrahepatic cholangiocarcinoma progression by recruiting YBX1 to
initiate FZD7 transcription. J Hepatol. 76:135–147. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang Q, Hao X, Xu G and Lv T:
Downregulated KIF3B induced by miR-605-3p inhibits the progression
of colon cancer via inactivating Wnt/β-Catenin. J Oncol.
2021:50469812021.PubMed/NCBI
|
|
16
|
Zeng Z, Zhou W, Duan L, Zhang J, Lu X, Jin
L and Yu Y: Circular RNA circ-VANGL1 as a competing endogenous RNA
contributes to bladder cancer progression by regulating
miR-605-3p/VANGL1 pathway. J Cell Physiol. 234:3887–3896. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu N, Hu G, Wang H, Wang Y and Guo Z:
LncRNA BLACAT1 regulates VASP expression via binding to miR-605-3p
and promotes giloma development. J Cell Physiol. 234:22144–22152.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hu YL, Feng Y, Chen YY, Liu JZ, Su Y, Li
P, Huang H, Mao QS and Xue WJ: SNHG16/miR-605-3p/TRAF6/NF-κB
feedback loop regulates hepatocellular carcinoma metastasis. J Cell
Mol Med. 24:7637–7651. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fei F, Li X, Xu L, Li D, Zhang Z, Guo X,
Yang H, Chen Z and Xing J: CD147-CD98hc complex contributes to poor
prognosis of non-small cell lung cancer patients through promoting
cell proliferation via the PI3K/Akt signaling pathway. Ann Surg
Oncol. 21:4359–4368. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu C, Li X, Li C, Zhang Z, Gao X, Jia Z,
Chen H, Jia Q, Zhao X, Liu J, et al: SLC3A2 is a novel endoplasmic
reticulum stress-related signaling protein that regulates the
unfolded protein response and apoptosis. PLoS One. 13:e02089932018.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Palacín M and Kanai Y: The ancillary
proteins of HATs: SLC3 family of amino acid transporters. Pflugers
Arch. 447:490–494. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
He J, Liu D, Liu M, Tang R and Zhang D:
Characterizing the role of SLC3A2 in the molecular landscape and
immune microenvironment across human tumors. Front Mol Biosci.
9:9614102022. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Koppula P, Zhuang L and Gan B: Cystine
transporter SLC7A11/xCT in cancer: Ferroptosis, nutrient
dependency, and cancer therapy. Protein Cell. 12:599–620. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Digomann D, Linge A and Dubrovska A:
SLC3A2/CD98hc, autophagy and tumor radioresistance: A link
confirmed. Autophagy. 15:1850–1851. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ma L, Zhang X, Yu K, Xu X, Chen T, Shi Y,
Wang Y, Qiu S, Guo S, Cui J, et al: Targeting SLC3A2 subunit of
system XC− is essential for m6A
reader YTHDC2 to be an endogenous ferroptosis inducer in lung
adenocarcinoma. Free Radic Biol Med. 168:25–43. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wu F, Xiong G, Chen Z, Lei C, Liu Q and
Bai Y: SLC3A2 inhibits ferroptosis in laryngeal carcinoma via mTOR
pathway. Hereditas. 159:62022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu H, Deng Z, Yu B, Liu H, Yang Z, Zeng A
and Fu M: Identification of SLC3A2 as a potential therapeutic
target of osteoarthritis involved in ferroptosis by integrating
bioinformatics, clinical factors and experiments. Cells.
11:34302022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hu Z, Yin Y, Jiang J, Yan C, Wang Y, Wang
D and Li L: Exosomal miR-142-3p secreted by hepatitis B virus
(HBV)-hepatocellular carcinoma (HCC) cells promotes ferroptosis of
M1-type macrophages through SLC3A2 and the mechanism of HCC
progression. J Gastrointest Oncol. 13:754–767. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Qin X, Zhang J, Wang B, Xu G, Yang X, Zou
Z and Yu C: Ferritinophagy is involved in the zinc oxide
nanoparticles-induced ferroptosis of vascular endothelial cells.
Autophagy. 17:4266–4285. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shang A, Gu C, Wang W, Wang X, Sun J, Zeng
B, Chen C, Chang W, Ping Y, Ji P, et al: Exosomal circPACRGL
promotes progression of colorectal cancer via the
miR-142-3p/miR-506-3p- TGF-β1 axis. Mol Cancer. 19:1172020.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Krenzien F, Nevermann N, Krombholz A,
Benzing C, Haber P, Fehrenbach U, Lurje G, Pelzer U, Pratschke J,
Schmelzle M and Schöning W: Treatment of intrahepatic
cholangiocarcinoma-a multidisciplinary approach. Cancers (Basel).
14:3622022. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yang J, Qi M, Fei X, Wang X and Wang K:
Hsa_circRNA_0088036 acts as a ceRNA to promote bladder cancer
progression by sponging miR-140-3p. Cell Death Dis. 13:3222022.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Du J, Lan T, Liao H, Feng X, Chen X, Liao
W, Hou G, Xu L, Feng Q, Xie K, et al: CircNFIB inhibits tumor
growth and metastasis through suppressing MEK1/ERK signaling in
intrahepatic cholangiocarcinoma. Mol Cancer. 21:182022. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jiang XM, Li ZL, Li JL, Xu Y, Leng KM, Cui
YF and Sun DJ: A novel prognostic biomarker for cholangiocarcinoma:
circRNA Cdr1as. Eur Rev Med Pharmacol Sci. 22:365–371.
2018.PubMed/NCBI
|
|
36
|
Zhou D, Gao B, Yang Q, Kong Y and Wang W:
Integrative analysis of ceRNA network reveals functional lncRNAs in
intrahepatic cholangiocarcinoma. Biomed Res Int. 2019:26012712019.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kang Z, Guo L, Zhu Z and Qu R:
Identification of prognostic factors for intrahepatic
cholangiocarcinoma using long non-coding RNAs-associated ceRNA
network. Cancer Cell Int. 20:3152020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Xu YP, Dong ZN, Wang SW, Zheng YM, Zhang
C, Zhou YQ, Zhao YJ, Zhao Y, Wang F, Peng R, et al: circHMGCS1-016
reshapes immune environment by sponging miR-1236-3p to regulate
CD73 and GAL-8 expression in intrahepatic cholangiocarcinoma. J Exp
Clin Cancer Res. 40:2902021. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tang J, Wang R, Tang R, Gu P, Han J and
Huang W: CircRTN4IP1 regulates the malignant progression of
intrahepatic cholangiocarcinoma by sponging miR-541-5p to induce
HIF1A production. Pathol Res Pract. 230:1537322022. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cano-Crespo S, Chillarón J, Junza A,
Fernández-Miranda G, García J, Polte C, R de la Ballina L, Ignatova
Z, Yanes Ó, Zorzano A, et al: CD98hc (SLC3A2) sustains amino acid
and nucleotide availability for cell cycle progression. Sci Rep.
9:140652019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Furuya M, Horiguchi J, Nakajima H, Kanai Y
and Oyama T: Correlation of L-type amino acid transporter 1 and
CD98 expression with triple negative breast cancer prognosis.
Cancer Sci. 103:382–389. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhu B, Cheng D, Hou L, Zhou S, Ying T and
Yang Q: SLC3A2 is upregulated in human osteosarcoma and promotes
tumor growth through the PI3K/Akt signaling pathway. Oncol Rep.
37:2575–2582. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Li W, Dong X, He C, Tan G, Li Z, Zhai B,
Feng J, Jiang X, Liu C, Jiang H and Sun X: LncRNA SNHG1 contributes
to sorafenib resistance by activating the Akt pathway and is
positively regulated by miR-21 in hepatocellular carcinoma cells. J
Exp Clin Cancer Res. 38:1832019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Janpipatkul K, Suksen K, Borwornpinyo S,
Jearawiriyapaisarn N, Hongeng S, Piyachaturawat P and Chairoungdua
A: Downregulation of LAT1 expression suppresses cholangiocarcinoma
cell invasion and migration. Cell Signal. 26:1668–1679. 2014.
View Article : Google Scholar : PubMed/NCBI
|
